U.S. License Holder:
Date of License:
IMJUDO (tremelimumab-actl) s a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated:
In combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC);
In combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
U.S. Patent LitigationsPACER
U.S. Patent Nos.
9,273,135 (Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1) 9,320.811 (Combination of Anti-CTLA4 Antibody with Diverse Therapeutic Regimens for the Synergistic Treatment of Proliferative Diseases)
Bristol-Myers Squibb Co.; ER Squibb & Sons, LLC
AstraZeneca AB; AstraZeneca Pharmaceuticals LP